ClinicalTrials.gg
RecruitingNCT05195905Updated Oct 16, 2026

PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm

An interventional study of PMEG in Pararenal Aortic Aneurysm and Thoracoabdominal Aortic Aneurysm, sponsored by Konstantinos Arnaoutakis, MD. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Konstantinos Arnaoutakis, MD · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.
Updated Oct 16, 2026Results publication addedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States — 15 open to participants now, 18 under way, none of them phase 3. Aortic Aneurysm, Thoracoabdominal · United States.

Planned enrollment
5th of 24
300 · median 126
Started
2023
with 1 other
No phase
21 of 26
13 open now
Primary completion
2030-02
later than 14 of 17 live
Registered
21st of 26
by date

Among the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, this one is the 5th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2023, is one of 21 with no phase, reaches primary completion later than 14 of the 17 other live ones, and was the 21st registered.

Aortic Aneurysm, Thoracoabdominal

63 studies on the registry are indexed under Aortic Aneurysm, Thoracoabdominal; 31 are open to participants now.

Browse Aortic Aneurysm, Thoracoabdominal studies →

Open to participants now

15 of the 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 25 Aortic Aneurysm, Thoracoabdominal studies recruiting now, 18 (72%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Aortic Aneurysm, Thoracoabdominal with a site in United States, or all of them as a file.
02

Study summary

The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.

03

Conditions studied

  • Pararenal Aortic Aneurysm
  • Thoracoabdominal Aortic Aneurysm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form
  2. Male or female, aged ≥18 years
  3. Expected survival beyond 1 year following successful aneurysm repair
  4. Anatomy that would require coverage of the celiac artery, superior mesenteric artery (SMA), and/or renal arteries if conventional, FDA-approved endograft were implanted to obtain adequate sealing zone length
  5. Aneurysm of the thoracoabdominal or pararenal aorta with or without chronic dissection
  6. Adequate proximal zone of fixation
  7. Adequate distal zone of fixation
  8. No more than 5 non-aneurysmal visceral (celiac, SMA, or renal) arteries with diameters between 4-12mm
  9. Adequate arterial access for delivery system; use of iliac conduit is permitted as necessary

Exclusion criteria

Exclusion Criteria:

  1. Moderate-to-severe aortic neck calcification, thrombus, or tortuosity
  2. Severe iliac stenosis, calcification, or tortuosity with no ability to perform a conduit
  3. Proximal landing within zone 0 or 1
  4. Inability to maintain at least one patent hypogastric artery
  5. Freely ruptured aneurysm with hemodynamic instability
  6. Non-ambulatory status
  7. Severe CHF
  8. Baseline \< 30ml/min, unless currently on or to be initiating dialysis
  9. Unstable angina
  10. Stroke or MI within 3 months of planned treatment date
  11. Active systemic infection and/or mycotic aneurysm
  12. Uncorrectable coagulopathy or other bleeding diathesis
  13. Known allergy to device material or contrast material that cannot be adequately pre-medicated
  14. Body habitus that would preclude adequate fluoroscopic visualization of aorta
  15. Pregnancy or lactation (confirmed per standard of care surgical practice)
  16. Major, unrelated surgical procedure planned ≤30 days from endovascular repair
  17. Patient is ≤30 days beyond primary endpoint for another investigative clinical drug/device trial
  18. Social or psychological issues that would interfere with ability to comply with all study procedures for the duration of the study
  19. Can be treated in accordance with the instructions for use with a legally marketed endovascular device, including a manufacturer-fabricated custom device
  20. Can enroll in a manufacturer-sponsored clinical study at our institution or is willing and eligible to participate in a study with a manufacturer-made device at another institution
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Physician-modified endografts

    For this clinical protocol, endografts which are commercially available will be modified in a sterile fashion on a back-table in the operating room.

    Device: PMEG

Interventions

  • DevicePMEG

    All devices that will be modified in this study protocol are commercially available in the United States. The commercially available endografts will be used to construct a fenestrated/branched device for this intervention.

06

What researchers measure

Primary outcomes

  1. Number of subjects with 30-day major adverse events from primary procedure

    Major adverse events include: aortic-related mortality, major stroke, myocardial Infarction, permanent spinal cord ischemia, renal failure, bowel Ischemia (requiring laparotomy/bowel resection), respiratory failure (mechanical ventilation \>72 hours or requiring tracheostomy), lower extremity ischemia, blood loss ≥1,000cc

    Time frame: Day 30

  2. Number of subjects with treatment success

    Treatment success is defined as a composite of: technical success, device integrity (freedom from stent fractures), freedom from aortic enlargement ≥5mm compared to preoperative CT imaging, freedom from aortic rupture, freedom from reintervention for type I or III endoleak or patency-related event, freedom from conversion to open aneurysm repair, freedom from aneurysm-related mortality.

    Time frame: Month 12

Secondary outcomes

  1. Number of subjects with mortality, major adverse events, spinal cord ischemia

    Mortality includes all-cause mortality. Major adverse events include: aortic-related mortality, major stroke, myocardial Infarction, permanent spinal cord ischemia, renal failure, bowel Ischemia (requiring laparotomy/bowel resection), respiratory failure (mechanical ventilation \>72 hours or requiring tracheostomy), lower extremity ischemia, blood loss ≥1,000cc. Spinal cord ischemia data will include all incidence and degree of spinal cord ischemia.

    Time frame: Day 30, Month 6, Month 12, Month 24, Month 36, Month 48, Month 60

  2. Number of subjects with treatment success and freedom from secondary intervention

    Treatment success is defined as a composite of: technical success, device integrity (freedom from stent fractures), freedom from aortic enlargement ≥5mm compared to preoperative CT imaging, freedom from aortic rupture, freedom from reintervention for type I or III endoleak or patency-related event, freedom from conversion to open aneurysm repair, freedom from aneurysm-related mortality. Freedom from secondary interventions includes interventions to treat malperfusion, rupture, aneurysm formation, aortic expansion, endoleak, device stenosis/occlusion, or access site complication.

    Time frame: Day 30, Month 6, Month 12, Month 24, Month 36, Month 48, Month 60

07

Study locations

1 of 1 sites recruiting
  • Orlando Health Wiregrass Ranch Hospital
    Wesley Chapel, Florida 33543, United States
    Recruiting
08

References and documents

Publications

  • Dossabhoy SS, Simons JP, Flahive JM, Aiello FA, Sheth P, Arous EJ, Messina LM, Schanzer A. Fenestrated endovascular aortic aneurysm repair using physician-modified endovascular grafts versus company-manufactured devices. J Vasc Surg. 2018 Jun;67(6):1673-1683. doi: 10.1016/j.jvs.2017.10.055. Epub 2017 Dec 8. PubMed 29224942 ↗
  • Oderich GS, Ribeiro MS, Sandri GA, Tenorio ER, Hofer JM, Mendes BC, Chini J, Cha S. Evolution from physician-modified to company-manufactured fenestrated-branched endografts to treat pararenal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2019 Jul;70(1):31-42.e7. doi: 10.1016/j.jvs.2018.09.063. Epub 2018 Dec 21. PubMed 30583902 ↗
  • Eagleton MJ, Follansbee M, Wolski K, Mastracci T, Kuramochi Y. Fenestrated and branched endovascular aneurysm repair outcomes for type II and III thoracoabdominal aortic aneurysms. J Vasc Surg. 2016 Apr;63(4):930-42. doi: 10.1016/j.jvs.2015.10.095. Epub 2016 Jan 11. PubMed 26792544 ↗
  • Schanzer A, Simons JP, Flahive J, Durgin J, Aiello FA, Doucet D, Steppacher R, Messina LM. Outcomes of fenestrated and branched endovascular repair of complex abdominal and thoracoabdominal aortic aneurysms. J Vasc Surg. 2017 Sep;66(3):687-694. doi: 10.1016/j.jvs.2016.12.111. Epub 2017 Mar 1. PubMed 28259577 ↗
  • Oderich GS, Ribeiro M, Hofer J, Wigham J, Cha S, Chini J, Macedo TA, Gloviczki P. Prospective, nonrandomized study to evaluate endovascular repair of pararenal and thoracoabdominal aortic aneurysms using fenestrated-branched endografts based on supraceliac sealing zones. J Vasc Surg. 2017 May;65(5):1249-1259.e10. doi: 10.1016/j.jvs.2016.09.038. Epub 2016 Dec 13. PubMed 27986479 ↗
  • Conrad MF, Crawford RS, Davison JK, Cambria RP. Thoracoabdominal aneurysm repair: a 20-year perspective. Ann Thorac Surg. 2007 Feb;83(2):S856-61; discussion S890-2. doi: 10.1016/j.athoracsur.2006.10.096. PubMed 17257941 ↗
  • Coselli JS, Bozinovski J, LeMaire SA. Open surgical repair of 2286 thoracoabdominal aortic aneurysms. Ann Thorac Surg. 2007 Feb;83(2):S862-4; discussion S890-2. doi: 10.1016/j.athoracsur.2006.10.088. PubMed 17257942 ↗
  • Schepens MA, Heijmen RH, Ranschaert W, Sonker U, Morshuis WJ. Thoracoabdominal aortic aneurysm repair: results of conventional open surgery. Eur J Vasc Endovasc Surg. 2009 Jun;37(6):640-5. doi: 10.1016/j.ejvs.2009.03.011. Epub 2009 Apr 11. PubMed 19362499 ↗
  • Arnaoutakis DJ, Scali ST, Beck AW, Kubilis P, Huber TS, Martin AJ, Laquian L, Back M, Giles KA, Fatima J, Beaver TM, Upchurch GR Jr. Comparative outcomes of open, hybrid, and fenestrated branched endovascular repair of extent II and III thoracoabdominal aortic aneurysms. J Vasc Surg. 2020 May;71(5):1503-1514. doi: 10.1016/j.jvs.2019.08.236. Epub 2019 Nov 11. PubMed 31727462 ↗
  • Scali ST, Kim M, Kubilis P, Feezor RJ, Giles KA, Miller B, Fatima J, Huber TS, Berceli SA, Back M, Beck AW. Implementation of a bundled protocol significantly reduces risk of spinal cord ischemia after branched or fenestrated endovascular aortic repair. J Vasc Surg. 2018 Feb;67(2):409-423.e4. doi: 10.1016/j.jvs.2017.05.136. Epub 2017 Oct 7. PubMed 29017806 ↗
  • Nguyen T, Gittinger M, Gryzbowski C, Patel S, Asirwatham M, Grundy S, Zwiebel B, Shames M, Arnaoutakis DJ. One-hundred Consecutive Physician-Modified Fenestrated Endovascular Aneurysm Repair of Pararenal and Thoracoabdominal Aortic Aneurysms Using the Terumo TREO Stent Graft. Ann Vasc Surg. 2024 Sep;106:369-376. doi: 10.1016/j.avsg.2024.04.009. Epub 2024 May 31. PubMed 38823478 ↗
  • Asirwatham M, Konanki V, Lucas SJ, Grundy S, Zwiebel B, Shames M, Arnaoutakis DJ. Comparative outcomes of physician-modified fenestrated/branched endovascular aortic aneurysm repair in the setting of prior failed endovascular aneurysm repair. J Vasc Surg. 2023 Nov;78(5):1153-1161. doi: 10.1016/j.jvs.2023.07.002. Epub 2023 Jul 13. PubMed 37451371 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2023 (actual). Primary completion is estimated for Feb 2030, 80 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Feb 2029 → Feb 2030 and completion Aug 2029 → Feb 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2022
First posted
Jan 19, 2022
StartActual
Jun 6, 2023
Primary completionEst.
Feb 2030was Feb 2029
CompletionEst.
Feb 2030was Aug 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 2 sites removed
Show site
  • Orlando Health Wiregrass Ranch Hospital · Wesley Chapel, United States
Show 2 removed
  • Tampa General Hospital · Tampa, United States
  • University of South Florida - South Tampa Campus · Tampa, United States
Oct 16, 2026
Primary completion
Feb 2029→Feb 2030
Oct 16, 2026
Study completion
Aug 2029→Feb 2030
Oct 16, 2026
Enrollment
30→300
Oct 16, 2026
Publications
Results publication added: Nguyen T, Gittinger M, Gryzbowski C, Patel S, Asirwatham M, Grundy S, Zwiebel B, Shames M, Arnaoutakis DJ. One-hundred Consecutive Physician-Modified Fenestrat… PubMed 38823478 ↗; 1 more
Oct 16, 2026
Contact
Study contact changed: b•••@usf.edu · •••7948→j•••@orlandohealth.com · •••3781; a•••@usf.edu→d•••@orlandohealth.com. See the current contact
Oct 16, 2026
Sponsor
Konstantinos Dean Arnaoutakis, MD→Konstantinos Arnaoutakis, MD
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Publications Results publication added: Nguyen T, Gittinger M, Gryzbowski C, Patel S, Asirwatham M, Grundy S, Zwiebel B, Shames M, Arnaoutakis DJ. One-hundred Consecutive Physician-Modified Fenestrat… PubMed 38823478 ↗; 1 more
    1 site added, 2 sites removed
    Show site
    • Orlando Health Wiregrass Ranch Hospital · Wesley Chapel, United States
    Show 2 removed
    • Tampa General Hospital · Tampa, United States
    • University of South Florida - South Tampa Campus · Tampa, United States
    Primary completion Feb 2029→Feb 2030
    Study completion Aug 2029→Feb 2030
    Enrollment 30→300
    Sponsor Konstantinos Dean Arnaoutakis, MD→Konstantinos Arnaoutakis, MD
    Contact Study contact changed: b•••@usf.edu · •••7948→j•••@orlandohealth.com · •••3781; a•••@usf.edu→d•••@orlandohealth.com. See the current contact
    + 3 other changes: index terms, identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05195905
Lead sponsor
Konstantinos Arnaoutakis, MD
Collaborators
Orlando Health, Inc.
Responsible party
Konstantinos Arnaoutakis, MD (Vascular Surgeon, Orlando Health, Inc.) — Sponsor-investigator
First posted
Jan 19, 2022
Start date
Jun 6, 2023
Primary completion
Feb 2030 (estimated)
Completion
Feb 2030 (estimated)
Last update
Oct 16, 2026

Study contacts

Janelle Barrera, MPH
Contact
janelle.barreraikan@orlandohealth.com
813-802-3781
Konstantinos Dean Arnaoutakis, MD
Contact
dean.arnaoutakis@orlandohealth.com
Konstantinos Dean Arnaoutakis, MD
principal investigator · Orlando Health - Florida Medical Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion